Roche Unveils $50 Billion Five-Year US Investment Plan to Expand Manufacturing and R&D
Company

Roche Unveils $50 Billion Five-Year US Investment Plan to Expand Manufacturing and R&D

China Medical System Announces Spin-off of Dermavon for HKEX IPO
CompanyDeals

China Medical System Announces Spin-off of Dermavon for HKEX IPO

BMS's Cobenfy Shows Promise in Phase III ARISE Trial for Schizophrenia
CompanyDrug

BMS’s Cobenfy Shows Promise in Phase III ARISE Trial for Schizophrenia

CSPC Gains NMPA Approval for Phase III Trial of Prusogliptin/Metformin FDC
CompanyDrug

CSPC Gains NMPA Approval for Phase III Trial of Prusogliptin/Metformin FDC

CSPC Pharmaceutical Gains FDA IND Clearance for JMT203 in Cancer Cachexia
CompanyDrug

CSPC Pharmaceutical Gains FDA IND Clearance for JMT203 in Cancer Cachexia

Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray
CompanyDrug

Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray

Biokin Receives NMPA Approval for CD33 ADC in AML Trial
CompanyDrug

Biokin Receives NMPA Approval for CD33 ADC in AML Trial

Fujifilm Diosynth Secures $3 Billion US Manufacturing Pact with Regeneron
CompanyDeals

Fujifilm Diosynth Secures $3 Billion US Manufacturing Pact with Regeneron

Hotgen Biotech Injects RMB 300 Million into Subsidiary Shunjing Bio for Biologic R&D
CompanyDeals

Hotgen Biotech Injects RMB 300 Million into Subsidiary Sungen Bio for Biologic R&D

NMPA Issues 91st Batch of Reference Standards for Generic Drug Quality Evaluation
Policy / Regulatory

NMPA Issues 91st Batch of Reference Standards for Generic Drug Quality Evaluation

United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices
CompanyDeals

United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices

Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment
CompanyMedical Device

Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment